Cargando…
Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only curative treatment. However, fewer than 20% of patients are candidates for surgery at the time of presentation....
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225994/ https://www.ncbi.nlm.nih.gov/pubmed/32325731 http://dx.doi.org/10.3390/cancers12041002 |